The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 0.00 (0.00%)
Spread: 0.50 (0.029%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

GSK exec caught off-guard by China graft charges: sources

Thu, 15th May 2014 09:14

By Adam Jourdan and Kazunori Takada

SHANGHAI, May 15 (Reuters) - GlaxoSmithKline Plc executive Mark Reilly had little inkling he would be chargedwith leading a network of corruption in China's pharmaceuticalindustry, two sources with ties to the businessman and knowledgeof the investigation said.

The allegations against the Briton, who as GSK's China headwas the firm's legal representative in the country, are the mostserious charges ever laid against a foreign national forcorporate corruption in China, lawyers said.

Police said they had charged Reilly and two Chinesecolleagues with multiple offences on Wednesday, after a 10-monthprobe found the firm made billions of yuan from schemes to bribedoctors and hospitals.

"The fact that Mark's name was on the list of people chargedwas definitely a surprise," said a source with direct knowledgeof the investigation. The source declined to be named because ofthe sensitivity of the case.

Police findings are usually upheld in Chinese courts,meaning Reilly and the other executives could face decades injail.

GSK did not respond to requests for comment on Thursday.

Britain's biggest drugmaker said in a statement on Wednesdaythat the allegations were "deeply concerning" and it hoped to"reach a resolution" that would enable it to continue to operatein China, a key growth market for Western pharmaceutical giants.

Reilly, a scientist and accountant who has been with GSK forover two decades, briefly left China after the scandal broke inJuly last year. He voluntarily returned to assist authoritieswith the probe, with insiders saying the understanding was thiswould shield him from charges.

"I've had regular contact with Mark over the past fewmonths. I would think that this state of affairs is a surpriseto him. I don't think he is prepared, or thought that he couldbe culpable," an industry executive in China who has personalties to Reilly said.

Attempts to reach Reilly were unsuccessful.

NEXT STEPS

The last major corruption scandal to hit a foreign companyin China involved miner Rio Tinto in 2009,which resulted in four executives including a Chinese-bornAustralian being jailed for between seven and 14 years.

Reilly and two Chinese executives, Zhang Guowei and ZhaoHongyan, are charged with corporate bribery, bribingnon-government officials and bribing business units.

Officials gave no specific details on the amount of bribespaid or how much the company had illegally earned, althoughpreviously they accused the firm of funnelling up to 3 billionyuan ($482 million) to travel agencies to facilitate bribes todoctors and officials.

According to normal process, Reilly should have beendetained as soon as authorities laid charges against him.

Police could not be reached for comment and the Britishconsulate declined to comment on Reilly's whereabouts. Theindustry executive said he believed the Briton was still inShanghai.

Reilly had likely been barred from leaving China after hisreturn to help with the investigation, lawyers said.

WAKE-UP CALL

The prosecution will now examine the case before passing itto the courts, which could take as little as a month or muchlonger if further investigation is required, lawyers said.

GSK is the most prominent of a number of graft probes thathave been launched against global drug firms since last year,and authorities are unlikely to risk the investigation beingoverturned in the courts.

"For a sensitive and closely followed case like this, thepolice and prosecutors will have consulted with each otheralready," said Leon Liu, Shanghai-based partner at law firm MWEChina.

Chinese officials visited other international drugmakersincluding Novartis AG, AstraZeneca Plc, SanofiSA, Eli Lilly & C o and Bayer AG last year as part of a broad investigation into the sector,which is rife with bribery between sales staff and doctors.

Legal experts said the GSK case was a wake-up call toforeign companies that thought their top expatriate executiveswere immune from criminal charges as authorities step up acrackdown on corruption ordered by President Xi Jinping.

"There's a notion that only people of Chinese nationalityare going to go to jail here," said Steven Dickinson,Qingdao-based partner with law firm Harris Moure.

"People always say they'll never put a Briton or an Americanin jail. But they will, and this is just that example." (Additional reporting by John Ruwitch in SHANGHAI; Editing byStephen Coates)

More News
2 May 2024 19:57

GSK knew about Zantac cancer risk, attorneys tell jury in first trial

May 2 (Reuters) - U.S. attorneys for a woman who claims her colon cancer was caused by the now discontinued heartburn drug Zantac on Thursday told a jury in Chicago that pharmaceutical companies GSK and Boehringer Ingelheim knew the product could cause cancer if it was not handled properly but failed to warn the public.

Read more
2 May 2024 09:48

LONDON BROKER RATINGS: Deutsche Bank likes TP ICAP but says sell CMC

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

Read more
1 May 2024 19:39

Bird flu testing shows more dairy products are safe, US FDA says

CHICAGO, May 1 (Reuters) - Preliminary results of tests on additional dairy products show that pasteurization inactivates the bird flu virus, the U.S. Food and Drug Administration said on Wednesday.

Read more
1 May 2024 17:31

UK's FTSE 100 slips ahead of Fed outcome, energy stocks weigh

FTSE 100 down 0.3%, FTSE 250 off 0.2%

*

Read more
1 May 2024 16:56

LONDON MARKET CLOSE: FTSE 100 down ahead of US interest rate decision

(Alliance News) - Stock prices in London closed mostly in the red on Wednesday, as investors eye the latest interest rate decision from the US Federal Reserve this evening.

Read more
1 May 2024 16:42

London close: Stocks fall ahead of US Fed decision

(Sharecast News) - London markets closed lower on Wednesday, as investors digested the latest UK manufacturing data and anticipated an impending policy announcement from the US Federal Reserve.

Read more
1 May 2024 11:55

LONDON MARKET MIDDAY: FTSE 100 treads water as Fed takes centre-stage

(Alliance News) - London's FTSE 100 traded off session highs heading into Wednesday afternoon, as some pre-Federal Reserve decision nerves kicked in.

Read more
1 May 2024 10:54

GSK raises profit outlook on strong vaccine, HIV drug sales

FY profit forecast raised to 8-10%

*

Read more
1 May 2024 08:57

LONDON MARKET OPEN: FTSE 100 shakes off New York slump before Fed

(Alliance News) - Stock prices in London opened mixed on Wednesday, with the FTSE 100 brushing off some pre-Federal Reserve decision trepidation to record an early rise, while the dollar climbed on the expectation that Jerome Powell will sound hawkish in his press conference later.

Read more
1 May 2024 08:50

TOP NEWS: GSK expects momentum to continue after strong first quarter

(Alliance News) - GSK PLC on Wednesday raised its annual earnings forecast, and said it expects sales growth at the top-end of guidance, after a "strong" start to the year.

Read more
1 May 2024 07:46

LONDON BRIEFING: GSK ups outlook; Next first-quarter beats forecast

(Alliance News) - Equities in London are called to open flat on Wednesday, ahead of the latest Federal Reserve interest rate decision, while a host of financial markets in mainland Europe and beyond are closed for public holidays.

Read more
1 May 2024 07:36

GSK lifts annual guidance on strong virus treatment sales

(Sharecast News) - UK pharmaceutical giant GSK lifted annual profits guidance on Wednesday, as it pinned its hopes on demand for its respiratory virus and shingles treatments.

Read more
30 Apr 2024 23:46

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more
30 Apr 2024 22:39

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more
30 Apr 2024 13:51

Sensodyne maker Haleon to shut UK factory with loss of 435 jobs

(Alliance News) - More than 400 jobs are to be axed at Sensodyne toothpaste and Advil painkillers firm Haleon PLC as the group revealed plans to shut its only manufacturing site in the UK.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.